



NexoBrid is now part of data entry for patients entered in the BCQP Database

Please see Indications, including Limitations of Use, and IMPORTANT SAFETY INFORMATION below and on reverse side and Full Prescribing Information near this display or at <https://nexobrid-us.com/pdf/nexobrid-full-prescribing-information.pdf>

NexoBrid is available by prescription and should only be administered by a healthcare provider

About the Burn Care Quality Platform (BCQP)

- Per ABA's registry, the Burn Care Quality Platform (BCQP) is designed to improve the quality and cost of burn care by collecting and exchanging information on burn injuries and outcomes
- In March of 2024 the 'Enzymatic debridement (NexoBrid)' fields were added to the Resource Utilization form in the Burn Care Quality Platform
- Between March 2024 and February of 2025 the 'Enzymatic debridement (NexoBrid)' checkbox has been selected on 110 cases from 19 burn centers



Ensure NexoBrid is part of the BCQP—
notify your burn center's registrar today

The screenshot shows the 'RESOURCE UTILIZATION' form in the BCQP. A red arrow points to the 'Enzymatic debridement (NexoBrid)' checkbox, which is checked. Below it are fields for '% TBSA first application' and '% TBSA second application'. At the bottom, there are checkboxes for 'Body Area Treated' including Trunk, Lower Extremity, Upper Extremity, Hands, and Other.

If your Burn Center participates in the BCQP, add NexoBrid treatment to your patient files:

NexoBrid fields are available on the Resource Utilization Form on the A-F Tab

The checkbox is: 'Enzymatic debridement (NexoBrid)'

INDICATION

NEXOBRID® (anacaulase-bcdb) is indicated for eschar removal in adults and pediatric patients with deep partial thickness (DPT) and/or full thickness (FT) thermal burns.

Limitations of Use

The safety and effectiveness of NEXOBRID have not been established for treatment of:

- Chemical or electrical burns
- Burns on the face, perineum, or genitalia
- Burns on the feet of patients with diabetes mellitus or on the feet of patients with occlusive vascular disease
- Circumferential burns
- Burns in patients with significant cardiopulmonary disease, including inhalation injury

NEXOBRID is not recommended for:

- Wounds contaminated with radioactive and other hazardous substances to avoid unforeseeable reactions with the product and an increased risk of spreading the noxious substance
- Treatment of burn wounds where medical devices (e.g., implants, pacemakers, shunts) or vital structures (e.g., large vessels) could become exposed during eschar removal

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

NEXOBRID is contraindicated in patients with: known hypersensitivity to anacaulase-bcdb, bromelain, pineapples, or to any other components; known hypersensitivity to papayas or papain because of the risk of cross-sensitivity.

Please see additional IMPORTANT SAFETY INFORMATION on reverse side and Full Prescribing Information near this display or at <https://nexobrid-us.com/pdf/nexobrid-full-prescribing-information.pdf>

www.NexoBrid-US.com



Ensure NexoBrid is part of the BCQP—update your burn center’s registrar today

INDICATION

NEXOBRID® (anacaulase-bcdb) is indicated for eschar removal in adults and pediatric patients with deep partial thickness (DPT) and/or full thickness (FT) thermal burns.

Limitations of Use

The safety and effectiveness of NEXOBRID have not been established for treatment of:

- Chemical or electrical burns
- Burns on the face, perineum, or genitalia
- Burns on the feet of patients with diabetes mellitus or on the feet of patients with occlusive vascular disease
- Circumferential burns
- Burns in patients with significant cardiopulmonary disease, including inhalation injury

NEXOBRID is not recommended for:

- Wounds contaminated with radioactive and other hazardous substances to avoid unforeseeable reactions with the product and an increased risk of spreading the noxious substance
- Treatment of burn wounds where medical devices (e.g., implants, pacemakers, shunts) or vital structures (e.g., large vessels) could become exposed during eschar removal

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

NEXOBRID is contraindicated in patients with: known hypersensitivity to anacaulase-bcdb, bromelain, pineapples, or to any other components; known hypersensitivity to papayas or papain because of the risk of cross-sensitivity.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarketing use of anacaulase-bcdb. If a hypersensitivity reaction occurs, remove NEXOBRID (if applicable) and initiate appropriate therapy.

Healthcare personnel should take appropriate precautions to avoid exposure when preparing and handling NEXOBRID (e.g., gloves, surgical masks, other protective coverings, as needed).

Coagulopathy

Avoid use of NEXOBRID in patients with uncontrolled disorders of coagulation. Use with caution in patients on anticoagulant therapy or other drugs affecting coagulation, and in patients with low platelet counts and increased risk of bleeding from other causes. Monitor patients for possible signs of coagulation abnormalities and signs of bleeding.

ADVERSE REACTIONS

The most common adverse reactions (>5%) in adults were pruritus, pyrexia, wound complication, anemia, vomiting and insomnia. The most common adverse reactions (>5%) in pediatric patients were pruritus, pyrexia and vomiting.

USE IN SPECIAL POPULATIONS

Geriatric Use

Clinical studies of NEXOBRID did not include sufficient numbers of subjects 65 years of age and older to determine whether they respond differently from younger adult subjects.

To report negative side effects contact Vericel Corporation at 888-454-BURN (888-454-2876) or FDA at 1-800-FDA-1088 (1-800-332-1088) or www.fda.gov/medwatch.

Please see Full Prescribing Information near this display or at <https://nexobrid-us.com/pdf/nexobrid-full-prescribing-information.pdf>

www.NexoBrid-US.com